N/A N=112 SeCure Endovenous Laser Treatment Study
Chronic Venous Insufficiency
Primary: Acute Primary Ablation Success — 96 Veins
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=205 A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules
Rosacea
Primary: Investigator Global Assessment (IGA) 0=Clear, 1=Near Clear, 2=Mild, 3=Moderate, 4=Severe — 35; 15; 16; 6 Participants
Phase 2 N=4 A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)
Hypertension, Pulmonary
Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) — 0.936; 0.885; 0.813; 1.017 Ratio
Phase 2 N=50 L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels
Asthma · Inflammation
Primary: Number of Acute Exacerbation at 3 Months — 2.7; 2.2; 1.6; 2.2 Events — p=0.78
Phase 4 N=100 Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In India
Vaccines
Primary: Percentage of Participants Reporting Local Reactions by Severity Within 7 Days After Vaccination — 14.9; 14.9; 0; 0 percentage of participants
Phase 4 N=15 Hepatitis C Virus(HCV) Heart and Lung Study
Hepatitis C, Chronic · Heart Failure · Pulmonary Disease, Chronic Obstructive
Primary: Number of Subjects Who Completed 24 Weeks of Therapy — 0; 1 Participants
Phase 3 N=205 A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Myeloma
Primary: Progression-Free Survival (PFS) — 72; 50 Participants
Phase 1 N=72 Assessment of the Human Systemic Absorption of Sunscreen Ingredients
Systemic Exposure to Sunscreen Ingredients
Primary: Avobenzone Maximum Concentration — 1.8; 4.3; 4.0; 3.4 ng/mL
Phase 4 N=196 Prevention of OM-85 on Bronchiectasis Exacerbation
Bronchiectasis With Acute Exacerbation
Primary: Bronchiectasis Exacerbation — 0.98; 0.75 proportion of acute exacerbations
Phase 4 N=61 Inositol and Omega-3 Fatty Acids in Pediatric Mania
Pediatric Bipolar Spectrum Disorders
Primary: Improvement in Mania Symptoms by Change in Young Mania Rating Scale (YMRS) — -4.8; -6.4; -10.2 units on a scale
N/A N=60 Repetitive Activation Patterns and Focal Impulses Identification and Ablation in Persistent AF
Persistent Atrial Fibrillation
Primary: Percentage of Participants With Acute Success Post CartoFinder Guided Ablation (CFGA) Only (Before Pulmonary Vein Isolation [PVI] and Without Cardioversion). — 22.9…
N/A N=7 Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR
Acute Lymphoblastic Leukemia · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Antibody Recall Response Rate — 0.167 proportion of participants
Phase 3 N=816 Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
Severe Sepsis · Coagulopathy
Primary: Number of Participants With 28-Day All-cause Mortality — 106; 119 Participants — p=0.318
Phase 3 N=373 Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma
Asthma
Primary: Mean Change From Start of Treatment Baseline to End of Study (Week 12) for In-clinic Morning Pre-Dose Forced Expiratory Volume In 1 Second (FEV1) — 0.19; 0.32; 0.38…
N/A N=64 RADAR Clinical Trial
Persistent Atrial Fibrillation
Primary: Number of Participants With Atrial Fibrillation Termination — 23; 12 Participants